Prostate Cell News Volume 3.42 | Nov 2 2012

LABORATORY RESEARCH

A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease
Researchers undertook this study to analyze the ‘galectin signature’ of the human prostate cancer microenvironment with the overarching goal of selecting novel molecular targets for prognostic and therapeutic purposes. [Cancer Res] Abstract

Increased PrLZ-Mediated Androgen Receptor Transactivation Promotes Castration Resistant Prostate Cancer Growth
Scientists found PrLZ, a newly identified Prostate Leucine Zipper gene that is highly expressed in advanced prostate cancers could interact with the androgen receptor (AR) directly leading to enhance AR transactivation in the castration resistant condition. [Carcinogenesis] Abstract

Myoblasts Inhibit Prostate Cancer Growth by Paracrine Secretion of TNF Alpha
Researchers investigated the interactions between myoblasts and prostate carcinoma cells in vitro and in vivo. [J Urol] Abstract

Transcript Levels of Androgen Receptor Variant AR-V1 or AR-V7 Do Not Predict Recurrence in Patients with Prostate Cancer at Indeterminate Risk for Progression
Scientists investigated whether androgen receptor (AR)-V7 or V1 expression would predict biochemical recurrence in men at indeterminate risk for progression following radical prostatectomy. [J Urol] Abstract

The Androgen Receptor: A Biologically Relevant Vaccine Target for the Treatment of Prostate Cancer
Researchers evaluated the immune and anti-tumor efficacy of a DNA vaccine targeting the androgen receptor ligand-binding domain in relevant rodent preclinical models. [Cancer Immunol Immunother] Abstract

Epigenetic Distortion to VDR Transcriptional Regulation in Prostate Cancer Cells
Investigators aimed to examine the gene specific mechanisms by which the actions of the vitamin D receptor (VDR) are distorted in prostate cancer. [J Steroid Biochem Mol Biol] Abstract

CLINICAL RESEARCH

A Randomized, Double-Blind, Multicenter, Phase II Study of a Human Monoclonal Antibody to Human αν Integrins (Intetumumab) in Combination with Docetaxel and Prednisone for the First-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
In a phase II, randomized, double-blind, multicenter study, men with metastatic castration-resistant prostate cancer without prior systemic nonhormonal therapy were randomly assigned to 75-mg/m² docetaxel (Taxotere) and 5-mg prednisone plus placebo or 10-mg/kg intetumumab three times weekly. [Ann Oncol] Abstract

Prospective Study on Metabolic Factors and Risk of Prostate Cancer
The authors found no evidence of an association between high levels of metabolic factors and the risk of prostate cancer, but high body mass index (BMI), elevated blood pressure, and a composite score of all metabolic factors were associated with an increased risk of death from prostate cancer. [Cancer] Abstract

Dietary Folate and Folate Vitamers and the Risk of Prostate Cancer in The Netherlands Cohort Study
Researchers aimed to examine the association between intake of folate, and specific folate vitamers, and the risk of advanced and total prostate cancer. [Cancer Causes Control] Abstract

The First Prostate Cancer Resource Center Comes to Lee County
The first Prostate Cancer Resource Center (PCRC) opened in Lee County, providing resources and support for the families who have been affected by prostate cancer. The PCRC is the first center in southwest Florida offering a free, open to the public environment providing support information, advocacy initiatives, clinical research opportunities, and answers for the cancer most commonly diagnosed in men- prostate cancer. [PR Newswire] Press Release

Movember & Sons 2012: Know why you Mo!
As men and women prepare themselves for Movember 2012 it’s important to be armed with knowledge of the impact your moustache and funds raised is having on men’s health. Movember is proud to announce that, to date, it has invested over $64 million to prostate cancer initiatives across Canada in the areas of awareness and education, research and survivorship. [Movember & Sons] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Tumor Invasion and Metastasis
January 20-23, 2013
San Diego, United States

Visit our events page to see a complete list of events in the prostate cell community.

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Postdoctoral Position – Prostate Cancer Metastasis (Lund University)

Research Associate – Quality Assurance (University of California)

Postdoctoral Position – Advanced Prostate Cancer Investigations (University of Texas Southwestern Medical Center)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Postdoctoral Position – Molecular Mechanisms of Advanced Prostate Cancer (UT Southwestern Medical Center)

Research Manager (Prostate Cancer UK)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.